vs

Side-by-side financial comparison of Assertio Holdings, Inc. (ASRT) and BayFirst Financial Corp. (BAFN). Click either name above to swap in a different company.

Assertio Holdings, Inc. is the larger business by last-quarter revenue ($13.5M vs $10.3M, roughly 1.3× BayFirst Financial Corp.). Over the past eight quarters, BayFirst Financial Corp.'s revenue compounded faster (-29.6% CAGR vs -35.4%).

Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As o...

The PNC Financial Services Group, Inc. is an American bank holding company and financial services corporation based in Pittsburgh, Pennsylvania. Its banking subsidiary, PNC Bank, operates in 27 states and the District of Columbia, with 2,629 branches and 9,523 ATMs. PNC Bank is one of the largest banks in the US by assets and by number of branches, deposits, and ATMs.

ASRT vs BAFN — Head-to-Head

Bigger by revenue
ASRT
ASRT
1.3× larger
ASRT
$13.5M
$10.3M
BAFN
Faster 2-yr revenue CAGR
BAFN
BAFN
Annualised
BAFN
-29.6%
-35.4%
ASRT

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ASRT
ASRT
BAFN
BAFN
Revenue
$13.5M
$10.3M
Net Profit
$-5.7M
Gross Margin
Operating Margin
-86.7%
Net Margin
-55.0%
Revenue YoY
-57.9%
Net Profit YoY
-130.6%
EPS (diluted)
$-4.54
$-1.48

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASRT
ASRT
BAFN
BAFN
Q1 26
$10.3M
Q4 25
$13.5M
$11.2M
Q3 25
$49.5M
$10.2M
Q2 25
$29.2M
$23.1M
Q1 25
$26.5M
$19.8M
Q4 24
$32.2M
$32.9M
Q3 24
$29.2M
$21.7M
Q2 24
$31.1M
$20.8M
Net Profit
ASRT
ASRT
BAFN
BAFN
Q1 26
$-5.7M
Q4 25
$-2.5M
Q3 25
$11.4M
$-18.9M
Q2 25
$-16.4M
$-1.2M
Q1 25
$-13.5M
$-335.0K
Q4 24
$9.8M
Q3 24
$-2.9M
$1.1M
Q2 24
$-3.7M
$866.0K
Operating Margin
ASRT
ASRT
BAFN
BAFN
Q1 26
Q4 25
-86.7%
-25.3%
Q3 25
23.2%
-253.0%
Q2 25
-27.5%
-7.1%
Q1 25
-50.0%
-2.3%
Q4 24
-41.9%
Q3 24
-10.4%
7.1%
Q2 24
-11.6%
5.9%
Net Margin
ASRT
ASRT
BAFN
BAFN
Q1 26
-55.0%
Q4 25
-22.1%
Q3 25
23.1%
-184.7%
Q2 25
-56.0%
-5.3%
Q1 25
-51.1%
-1.7%
Q4 24
91.8%
Q3 24
-10.0%
5.2%
Q2 24
-11.8%
4.2%
EPS (diluted)
ASRT
ASRT
BAFN
BAFN
Q1 26
$-1.48
Q4 25
$-4.54
$-0.71
Q3 25
$0.11
$-4.66
Q2 25
$-0.17
$-0.39
Q1 25
$-0.14
$-0.17
Q4 24
$-3.28
$2.21
Q3 24
$-0.03
$0.18
Q2 24
$-0.04
$0.12

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASRT
ASRT
BAFN
BAFN
Cash + ST InvestmentsLiquidity on hand
$63.4M
$134.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$94.0M
$81.9M
Total Assets
$267.0M
$1.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASRT
ASRT
BAFN
BAFN
Q1 26
$134.5M
Q4 25
$63.4M
$207.0M
Q3 25
$93.4M
$118.5M
Q2 25
$98.2M
$77.3M
Q1 25
$87.3M
$63.2M
Q4 24
$100.1M
$77.8M
Q3 24
$88.6M
$64.4M
Q2 24
$88.4M
$60.8M
Stockholders' Equity
ASRT
ASRT
BAFN
BAFN
Q1 26
$81.9M
Q4 25
$94.0M
$87.6M
Q3 25
$105.8M
$89.7M
Q2 25
$93.3M
$108.2M
Q1 25
$108.5M
$110.1M
Q4 24
$121.1M
$110.9M
Q3 24
$130.5M
$102.3M
Q2 24
$132.2M
$101.0M
Total Assets
ASRT
ASRT
BAFN
BAFN
Q1 26
$1.2B
Q4 25
$267.0M
$1.3B
Q3 25
$319.8M
$1.3B
Q2 25
$273.8M
$1.3B
Q1 25
$286.4M
$1.3B
Q4 24
$284.7M
$1.3B
Q3 24
$276.0M
$1.2B
Q2 24
$279.4M
$1.2B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASRT
ASRT
BAFN
BAFN
Operating Cash FlowLast quarter
$-30.0M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASRT
ASRT
BAFN
BAFN
Q1 26
Q4 25
$-30.0M
$285.3M
Q3 25
$-4.8M
$47.3M
Q2 25
$19.1M
$63.3M
Q1 25
$-12.5M
$74.2M
Q4 24
$11.5M
$390.5M
Q3 24
$-35.0K
$90.8M
Q2 24
$7.4M
$78.8M
Free Cash Flow
ASRT
ASRT
BAFN
BAFN
Q1 26
Q4 25
$285.0M
Q3 25
$47.3M
Q2 25
$63.1M
Q1 25
$74.1M
Q4 24
$388.8M
Q3 24
$90.5M
Q2 24
$78.4M
FCF Margin
ASRT
ASRT
BAFN
BAFN
Q1 26
Q4 25
2554.2%
Q3 25
462.2%
Q2 25
272.7%
Q1 25
375.1%
Q4 24
1180.9%
Q3 24
416.5%
Q2 24
376.1%
Capex Intensity
ASRT
ASRT
BAFN
BAFN
Q1 26
Q4 25
2.7%
Q3 25
0.1%
Q2 25
0.8%
Q1 25
0.4%
Q4 24
5.1%
Q3 24
0.0%
1.5%
Q2 24
1.9%
Cash Conversion
ASRT
ASRT
BAFN
BAFN
Q1 26
Q4 25
Q3 25
-0.42×
Q2 25
Q1 25
Q4 24
39.95×
Q3 24
79.85×
Q2 24
90.94×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASRT
ASRT

Products$12.8M95%
Other$719.0K5%

BAFN
BAFN

Net Interest Income$9.4M91%
Noninterest Income$884.0K9%

Related Comparisons